Zanamivir
Back to searchMolecule Structure
Scientific Name
Zanamivir
Description of the Drug
Zanamivir is a neuraminidase inhibitor used to treat influenza A and B.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB00558
http://www.drugbank.ca/drugs/DB00558
Brand Name(s)
Relenza
Company Owner(s)
Glaxosmithkline
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Neuraminidase | SINGLE PROTEIN | INHIBITOR | CHEMBL2051 |
| Neuraminidase | SINGLE PROTEIN | INHIBITOR | CHEMBL3377 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL9501 | |
| PharmGKB | PA164740891 | |
| Human Metabolome Database | HMDB0014698 | |
| DrugBank | DB00558 | |
| PubChem: Thomson Pharma | 14851079 | 14801980 |
| PubChem | 60855 | |
| Nikkaji | J680.760G | |
| PDBe | ZMR | |
| BindingDB | 50330326 | 4934 |
| EPA CompTox Dashboard | DTXSID0023749 | |
| DrugCentral | 2859 | |
| Brenda | 2693 | 224532 |
| ChemicalBook | CB0292498 | |
| rxnorm | ZANAMIVIR | RELENZA |
| PubChem: Drugs of the Future | 12014758 | |
| KEGG Ligand | C08095 | |
| ChEBI | 50663 | |
| ZINC | ZINC000003918138 |
